← Leaderboards
Marina A Jerebtsova
Howard University
$1,757,438
Attributed
$1,969,875
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $386.3K · FY2019–25$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,969,875 · 2
By mechanism
SC1$1,545,000 · 1
R21$424,875 · 1
Top collaborators
- Sergei Nekhai2 shared
Others in their field
Other Emerging Leaders on “Novel Therapeutics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$263,124,404
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
Research focus
Novel TherapeuticsBlood VesselsMacrophageComplexApoptosisEndotheliumEndothelial CellsInjuryMonocytePathway InteractionsMouse ModelMembraneAnatomyGenesComorbidityBiological MarkersBiologicalBeta GlobinCell LineBasic ScienceCore FacilityCell InjuryActivation ProductCohort
Grant awards (6)
The Role of Endothelial Injury and Myeloid Cell Migration in the Activation of Inflammasomes in HIV infection and Cocaine Exposure$193,125
R21 · FY2025 · DA
The Role of Endothelial Injury and Myeloid Cell Migration in the Activation of Inflammasomes in HIV infection and Cocaine Exposure$231,750
R21 · FY2024 · DA
The role of HGFL in the sickle cell disease nephropathy$386,250
SC1 · FY2022 · HL · contact PI
The role of HGFL in the sickle cell disease nephropathy$386,250
SC1 · FY2021 · HL · contact PI
The role of HGFL in the sickle cell disease nephropathy$386,250
SC1 · FY2020 · HL · contact PI
The role of HGFL in the sickle cell disease nephropathy$386,250
SC1 · FY2019 · HL · contact PI